SCHEMBL21311342

SCHEMBL21311342

CCCCCC(C)n1cnc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ASAH1 Q13510 1/20 0.45
ADA P00813 2/20 0.44
TDP1 Q9NUW8 1/20 0.41
SLC9A1 P19634 3/20 0.41
APAF1 O14727 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CNR1 P21554 3/20 0.39
CNR2 P34972 3/20 0.39
DNMT3A Q9Y6K1 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
TLR8 Q9NR97 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24421919 0.89 MEN1 (0.57) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL21917711 0.89 MEN1 (0.57) MEN1HPGDKMT2AHSD17B10ASAH1
Hydrochloric Acid SCHEMBL7246926 0.88 MEN1 (0.55) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL21559595 0.85 ASAH1 (0.51) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL4906610 0.85 MEN1 (0.53) MEN1HPGDKMT2AHSD17B10TDP1
SCHEMBL7854777 0.85 ASAH1 (0.51) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL21388677 0.85 ASAH1 (0.51) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL14740043 0.84 MEN1 (0.48) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL23940232 0.84 MEN1 (0.48) MEN1HPGDKMT2AHSD17B10ASAH1
SCHEMBL22810545 0.84 MEN1 (0.48) MEN1HPGDKMT2AHSD17B10ASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114787136-A Substituted benzimidazole carboxamides and their use in the treatment of medical disorders 比亚尔R&D投资股份公司 2022-07-22 CN disclosed
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190262371-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS POLRMT, EIF2AK2, NSUN3 MEN1 4786/4885HPGD 4689/4885KMT2A 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.